Altimmune Stock Discussion

$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...

9.50 is critical to hold. Under that will likely see 9.00 quickly. Here are the levels to watch.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$ $10

$Altimmune (ALT.US)$ If this breaks $10 there's no stopping

$Altimmune (ALT.US)$  Exciting times ..! In a market forecasted to be 100 billion by 2030, Altimmune phase 2 results are very promising going into phase 3 trials.
Will a partner be announced or are the rumours true a buy out is eminent..!

Here are the levels to watch on this push up.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Altimmune (Nasdaq: ALT) announced successful completion of End-of-Phase 2 Meeting with FDA for pemvidutide in obesity treatment. The company received agreement on Phase 3 registrational program design, which will include four Phase 3 trials (VELOCITY-1,2,3,4) enrolling approximately 5,000 subjects over 60-week periods. The trials will evaluate pemvidut...